This 37% gain bodes well for you

Article Excerpt

Eli Lilly’s shares haven’t just bounced back from their drop during the March market meltdown. In fact, they’ve soared to new all-time highs for investors and are now up a stellar 36.7% over the last year. What has spurred this strong performance? Well, it’s a combination of expanding investor interest in drug stocks, as well as the company’s own strong growth prospects. Drugmakers used to rely for their sales of “blockbuster drugs” that work on all patients. But now “personalized medicine” is thriving. This is where researchers use genetic and molecular information to create the best treatment plan for particular patients with similar profiles. This opens up a whole new market for smaller drugs that work on a range of smaller patient segments, but are highly effective and profitable. Another boost to drug stocks is a speeding up of approvals by the FDA—the U.S. Food and Drug Administration. This has accelerated during the COVID-19 crisis with more scrutiny and criticism of the agency’s…

You are trying to access subscriber-only content.

To read this article, you may subscribe or sign in.
If you are already a subscriber, log in here.

If you wish to become a subscriber, click here. Or you may enjoy access to all our publications when you become a Member of Pat McKeough's Inner Circle Pro.